New strategies for applying targeted therapies to adrenocortical carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Adrenocortical carcinoma (ACC) is a rare, aggressive endocrine malignancy with limited therapeutic options.
• High rates of metastatic disease and poor survival underscore the urgent need for novel treatment strategies.
• Current therapies offer minimal survival benefit, necessitating innovative approaches.

Purpose of the Study:

• To review recent findings from comprehensive molecular profiling of ACC.
• To discuss the identification of three distinct molecular subtypes of ACC.
• To explore the implications of these subtypes for targeted therapy development.

Main Methods:

• Analysis of comprehensive molecular profiling data from ACC patient cohorts.
• Integration of findings related to cell cycle, epigenetics, signaling pathways (Wnt/β-catenin, PKA), steroidogenesis, and immune cell biology.
• Review of recent clinical trial outcomes contextualized by molecular subtypes.

Main Results:

• ACC exhibits three clinically distinct molecular subtypes.
• These subtypes show differential regulation of key biological processes including cell cycle and signaling.
• Molecular profiling has enabled the development of subtype-specific biomarkers.

Conclusions:

• Understanding ACC molecular subtypes is crucial for advancing treatment strategies.
• Subtype-based biomarkers can refine patient stratification and trial design.
• Targeted therapies tailored to specific molecular subtypes hold promise for improving ACC patient outcomes.